ATLANTA, GA – – (Globe Newswire – February 5, 2026) – – A shareholder class action lawsuit has been filed against Mereo BioPharma Group plc (“Mereo” or the “Company”) (NASDAQ: MREO). The lawsuit alleges that Defendants issued false and misleading statements and/or failed to disclose material adverse facts, including allegations that Defendants concealed and misrepresented facts regarding setrusumab’s ability to achieve statistical significance for the primary endpoints in both the ORBIT and COSMIC studies.

If you purchased Mereo shares between June 5, 2023 and December 26, 2025, and experienced a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at cholzer@holzerlaw.com, by toll-free telephone at (888) 508-6832, or by visiting the firm’s website at www.holzerlaw.com/case/mereo-biopharma-group/ for more information.

The deadline to ask the court to be appointed lead plaintiff in the case is April 6, 2026.